Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Another update

<< Previous

Bullboard Posts

Next >>

Comment by Trogarzonon Jul 08, 2022 1:23pm

144 Views

Post# 34811422

RE:RE:RE:Another update

I retain from this information that it's complicated and not exactly conclusive atm. We need 30% tumor reduction to be considered a win... for now we have some regression and then some worsening. So much for the quick price fix I guess and the OO no.2 at 2$...

<< Previous

Bullboard Posts

Next >>

5 steps to mastering risk management in the stock market